Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NUVL NASDAQ:OCUL NASDAQ:PCVX NASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNUVLNuvalent$123.25-0.2%$103.86$71.13▼$123.62$9.75B1.153.98 million shs7.24 million shsOCULOcular Therapeutix$8.94+2.8%$8.90$6.23▼$16.44$1.90B0.892.37 million shs2.70 million shsPCVXVaxcyte$47.46+0.4%$54.50$29.08▼$65.00$6.83B1.241.44 million shs1.03 million shsPRAXPraxis Precision Medicines$266.58+7.5%$320.38$37.19▼$366.52$6.91B2.71467,933 shs423,170 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNUVLNuvalent+0.08%+31.30%+20.39%+26.06%+60.51%OCULOcular Therapeutix-0.46%-1.14%-5.02%-0.68%-1.36%PCVXVaxcyte+4.12%-3.01%-12.47%-13.36%+33.44%PRAXPraxis Precision Medicines+3.04%-6.33%-27.74%-15.64%+456.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNUVLNuvalent$123.25-0.2%$103.86$71.13▼$123.62$9.75B1.153.98 million shs7.24 million shsOCULOcular Therapeutix$8.94+2.8%$8.90$6.23▼$16.44$1.90B0.892.37 million shs2.70 million shsPCVXVaxcyte$47.46+0.4%$54.50$29.08▼$65.00$6.83B1.241.44 million shs1.03 million shsPRAXPraxis Precision Medicines$266.58+7.5%$320.38$37.19▼$366.52$6.91B2.71467,933 shs423,170 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNUVLNuvalent+0.08%+31.30%+20.39%+26.06%+60.51%OCULOcular Therapeutix-0.46%-1.14%-5.02%-0.68%-1.36%PCVXVaxcyte+4.12%-3.01%-12.47%-13.36%+33.44%PRAXPraxis Precision Medicines+3.04%-6.33%-27.74%-15.64%+456.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNUVLNuvalent 2.20Hold$131.156.41% UpsideOCULOcular Therapeutix 2.79Moderate Buy$23.78165.97% UpsidePCVXVaxcyte 2.63Moderate Buy$86.0081.21% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$572.72114.84% UpsideCurrent Analyst Ratings BreakdownLatest OCUL, NUVL, PRAX, and PCVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/10/2026NUVLNuvalent GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$151.00 ➝ $124.006/10/2026NUVLNuvalent UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$138.00 ➝ $124.006/10/2026NUVLNuvalent UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$138.00 ➝ $124.006/9/2026NUVLNuvalent Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$124.006/9/2026NUVLNuvalent TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$124.006/9/2026NUVLNuvalent BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$152.00 ➝ $124.006/9/2026NUVLNuvalent Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$122.856/9/2026NUVLNuvalent Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$124.006/9/2026NUVLNuvalent Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform6/2/2026PRAXPraxis Precision Medicines TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/AOCULOcular Therapeutix$51.95M37.68N/AN/A$3.07 per share2.91PCVXVaxcyteN/AN/AN/AN/A$20.51 per shareN/APRAXPraxis Precision Medicines$8.55M869.27N/AN/A$34.85 per share7.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)OCULOcular Therapeutix-$265.94M-$1.46N/AN/AN/A-558.24%-64.28%-48.15%8/4/2026 (Estimated)PCVXVaxcyte-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%8/5/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)Latest OCUL, NUVL, PRAX, and PCVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/6/2026Q1 2026PCVXVaxcyte-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNUVLNuvalentN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNUVLNuvalentN/A16.1416.14OCULOcular Therapeutix0.1214.8114.73PCVXVaxcyteN/A7.497.49PRAXPraxis Precision MedicinesN/A15.8815.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNUVLNuvalent97.26%OCULOcular Therapeutix59.21%PCVXVaxcyte96.78%PRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipNUVLNuvalent5.02%OCULOcular Therapeutix2.30%PCVXVaxcyte3.30%PRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNUVLNuvalent4079.00 million75.03 millionOptionableOCULOcular Therapeutix230218.96 million213.92 millionOptionablePCVXVaxcyte160144.40 million139.63 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.13 millionOptionableOCUL, NUVL, PRAX, and PCVX HeadlinesRecent News About These CompaniesPraxis Precision Medicines Shareholders Back Directors and Governance43 minutes ago | tipranks.comBTIG Reaffirms Buy Rating for Praxis Precision Medicines (PRAX)June 11 at 11:03 AM | finance.yahoo.comPraxis Precision Medicines, Inc. (PRAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comPraxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study FindingsJune 5, 2026 | finance.yahoo.comPraxis' Premium Price May Reflect Unrealistic Market Prospects In Essential TremorJune 5, 2026 | seekingalpha.comPraxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare ConferenceJune 4, 2026 | globenewswire.comPraxis Precision Medicines (PRAX) Receives a Buy from LifeSci CapitalJune 4, 2026 | theglobeandmail.comHC Wainwright Issues Pessimistic Outlook for PRAX EarningsJune 4, 2026 | marketbeat.comGeode Capital Management LLC Acquires 105,347 Shares of Praxis Precision Medicines, Inc. $PRAXJune 4, 2026 | marketbeat.comWhat is HC Wainwright's Forecast for PRAX FY2030 Earnings?June 3, 2026 | marketbeat.comPraxis pauses one of its seizure programs after phase 2 failJune 3, 2026 | fiercebiotech.comFPraxis down on trial setback for seizure therapyJune 3, 2026 | msn.comPraxis Precision Medicines Faces Vormatrigine Setback And Reassesses Epilepsy PipelineJune 3, 2026 | finance.yahoo.comThe shocking twist that sent this seizure-focused biotech into a diveJune 3, 2026 | msn.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2026 | globenewswire.comPraxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary EndpointJune 2, 2026 | benzinga.comPraxis Precision Medicines's Seizure Treatment Fails to Meet Trial's Primary EndpointJune 1, 2026 | marketwatch.comPRAX stock drops 12% after hours on trial setback — retail eyes FDA approval of other pipeline candidatesJune 1, 2026 | msn.comFDA Acceptance of Two CNS NDAs Might Change The Case For Investing In Praxis Precision Medicines (PRAX)June 1, 2026 | finance.yahoo.comPraxis Precision Medicines Shares Fall as Seizure Treatment Fails to Meet Trial's Primary Endpoint -- UpdateJune 1, 2026 | marketwatch.comPraxis Precision's epilepsy drug misses main goal of mid-to-late stage studyJune 1, 2026 | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 BillionBy Jeffrey Neal Johnson | June 11, 2026OCUL, NUVL, PRAX, and PCVX Company DescriptionsNuvalent NASDAQ:NUVL$123.25 -0.20 (-0.16%) Closing price 04:00 PM EasternExtended Trading$123.25 +0.00 (+0.00%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Ocular Therapeutix NASDAQ:OCUL$8.94 +0.24 (+2.76%) Closing price 04:00 PM EasternExtended Trading$8.82 -0.12 (-1.35%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Vaxcyte NASDAQ:PCVX$47.46 +0.17 (+0.36%) Closing price 04:00 PM EasternExtended Trading$47.44 -0.02 (-0.05%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Praxis Precision Medicines NASDAQ:PRAX$266.58 +18.60 (+7.50%) Closing price 04:00 PM EasternExtended Trading$270.00 +3.42 (+1.28%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
